FDA granted Fast Track designation for SGT-501, a therapy from Solid Biosciences Inc.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track designation for SGT-501, a therapy from Solid Biosciences Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA recommended advancement for a new drug application submitted by a company.
Coverage
Newest first; wire copies grouped- GlobeNewswireSolid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - SGT-501 has now received FDA Fast Trac